| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Executive VP, Global R&D
1 company
Fridriksdottir Hafrun serves as an Executive VP, Global R&D at TEVA. Across recent SEC filings that breaks down to 0 buys and 29 sells. Those positions are worth an estimated $11K at current prices.
Historically, Fridriksdottir Hafrun's trades have earned a below-average insider score of 47/100 across 7 rated trades. Over a 12-month horizon, 28.6% of those trades were profitable, with an average 12-month return of -10.6%.
The biggest single holding is TEVA (~$11K) as Executive VP, Global R&D. The recent filings there lean toward selling, a net 379,061 shares.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Nov 30, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Executive VP, Global R&D | Sale+OE | 933 | $21.76 | $20,304.04 | -9.6% | |
| Mar 19, 2018 | TEVA Teva Pharmaceutical Industries Ltd | Executive VP, Global R&D | Sale+OE | 348 | $17.88 | $6,221.54 | -4.7% |